Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Nystatin
Form:
10 of 10 products shown
6 general benefit · 4 not a benefit
Nyaderm · DIN 00716901 · 25000U/g · Vag Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Nyaderm · DIN 00716901
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-07-22 · brand NYADERM · ATC G01AA01 NYSTATIN · form Cream · route Vaginal · ingredients NYSTATIN 25000 UNIT/G · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
DIN 00716901: Nyaderm
Raw flags: sec3=Y
Item: 840408006; group id 823; item number 2007; lccId None; manufacturer id TAR
Source form: Vag Cr; strength: 25000U/g
Recorded listing: General benefit
Source prices (unrounded): $0.0834; ministry $0.0834
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716901
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9277Interchangeable products
Mycostatin · DIN 00295973 · not recorded
Shortage status: discontinued (October 4, 2024, reported by TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716901
Shortage record checked October 6, 2026
Nyaderm · DIN 00716871 · 100000U/g · Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Nyaderm · DIN 00716871
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
Health Canada: Marketed since 1979-12-31 · brand NYADERM · ATC D01AA01 NYSTATIN · form Cream · route Topical · ingredients NYSTATIN 100000 UNIT/G · company Taro pharmaceuticals inc · schedule Non-prescription drugs
DIN 00716871: Nyaderm
Raw flags: sec3=Y
Item: 840408004; group id 823; item number 2005; lccId None; manufacturer id TAR
Source form: Cr; strength: 100000U/g
Recorded listing: General benefit
Source prices (unrounded): $0.2037; ministry $0.2037
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716871
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8977
Therapeutic Notes (formulary)
Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.
Interchangeable products
Mycostatin · DIN 00029092 · not recorded
Shortage status: active shortage (reported August 1, 2026, estimated to end March 26, 2027, last updated August 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716871
Jamp-Nystatin Oral Suspension USP: Formulary list price $0.05 per unit (the source does not state the unit; exact figure $0.0518). What the ministry pays, not the patient.
Ministry pays: $0.0518 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02433443: Jamp-Nystatin Oral Suspension USP
Raw flags: sec3=Y
Item: 081204006; group id 14; item number 0018; lccId None; manufacturer id JPC
Source form: O/L; strength: 100000U/mL
Recorded listing: General benefit
Source prices (unrounded): $0.0518; ministry $0.0518
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02433443
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91783Interchangeable products
Mycostatin · DIN 00248169 · not recorded
Ratio-Nystatin · DIN 02194201 · $0.0518
Shortage status: resolved shortage (ended August 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02433443
Shortage record checked October 6, 2026
Ratio-Nystatin · DIN 02194201 · 100000U/mL · oral liquid
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ratio-Nystatin · DIN 02194201
Manufacturer: Ratiopharm Inc.; listing date 1997-10-31
Daily cost (source): $0.2072
Health Canada: Marketed since 2018-05-02 · brand TEVA-NYSTATIN · ATC A07AA02 NYSTATIN · form Suspension · route Oral · ingredients NYSTATIN 100000 UNIT/ML · company Teva canada limited · schedule Prescription
Ratio-Nystatin: Formulary list price $0.05 per unit (the source does not state the unit; exact figure $0.0518). What the ministry pays, not the patient.
Ministry pays: $0.0518 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02194201: Ratio-Nystatin
Raw flags: sec3=Y
Item: 081204006; group id 14; item number 0018; lccId None; manufacturer id RPH
Source form: O/L; strength: 100000U/mL
Recorded listing: General benefit
Source prices (unrounded): $0.0518; ministry $0.0518
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02194201
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35798Interchangeable products
Jamp-Nystatin Oral Suspension USP · DIN 02433443 · $0.0518
Mycostatin · DIN 00248169 · not recorded
Shortage status: active shortage (reported June 3, 2026, last updated June 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194201
Shortage record checked October 6, 2026
Ratio-Nystatin · DIN 02194228 · 100000U/g · Oint
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2021 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ratio-Nystatin · DIN 02194228
Manufacturer: Ratiopharm Inc.; listing date 1997-10-31
Health Canada: Cancelled post market since 2021-07-30 · brand RATIO-NYSTATIN · ATC D01AA01 NYSTATIN · form Ointment · route Topical · ingredients NYSTATIN 100000 UNIT/G · company Teva canada limited · schedule Non-prescription drugs
Ratio-Nystatin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1277). What the ministry pays, not the patient.
Ministry pays: $0.1277 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02194228: Ratio-Nystatin
Raw flags: sec3=Y
Item: 840408005; group id 823; item number 2006; lccId None; manufacturer id RPH
Source form: Oint; strength: 100000U/g
Recorded listing: General benefit
Source prices (unrounded): $0.1277; ministry $0.1277
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02194228
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35799
Therapeutic Notes (formulary)
Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.
Interchangeable products
Mycostatin · DIN 00029556 · not recorded
Shortage status: resolved shortage (ended July 10, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194228
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2021 — choose a marketed DIN from the same-category list.
Ratio-Nystatin · DIN 02194163 · 100000U/g · Vag Cr
General benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-17 — choose a marketed DIN from the same-category list.Discontinued January 17, 2020 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-01-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Ratio-Nystatin · DIN 02194163
Manufacturer: Ratiopharm Inc.; listing date 1997-10-31
Health Canada: Cancelled post market since 2020-01-17 · brand TEVA-NYSTATIN · ATC G01AA01 NYSTATIN · form Cream · route Vaginal · ingredients NYSTATIN 100000 UNIT/G · company Teva canada limited · schedule Prescription
Ratio-Nystatin: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3191). What the ministry pays, not the patient.
Ministry pays: $0.3191 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02194163: Ratio-Nystatin
Raw flags: sec3=Y
Item: 840408010; group id 823; item number 2008; lccId None; manufacturer id RPH
Source form: Vag Cr; strength: 100000U/g
Recorded listing: General benefit
Source prices (unrounded): $0.3191; ministry $0.3191
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02194163
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35795
Shortage status: discontinued (February 19, 2020, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194163
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 17, 2020 — choose a marketed DIN from the same-category list.
Mycostatin · DIN 00295973 · 25000U/g · Vag Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued August 1, 2005 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mycostatin · DIN 00295973
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Health Canada: Cancelled post market since 2005-08-01 · brand MYCOSTATIN VAGINAL CRM 25000UNIT · ATC G01AA01 NYSTATIN · form Cream · route Vaginal · ingredients NYSTATIN 25000 UNIT/G · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Prescription
Mycostatin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00295973: Mycostatin
Raw flags: notABenefit=Y, sec3=Y
Item: 840408006; group id 823; item number 2007; lccId None; manufacturer id BQU
Source form: Vag Cr; strength: 25000U/g
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00295973
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2082Interchangeable products
Nyaderm · DIN 00716901 · $0.0834
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00295973
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 1, 2005 — choose a marketed DIN from the same-category list.
Mycostatin · DIN 00029092 · 100000U/g · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-09-06 — choose a marketed DIN from the same-category list.Discontinued September 6, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-09-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-09-06 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mycostatin · DIN 00029092
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Health Canada: Cancelled post market since 2006-09-06 · brand MYCOSTATIN CRM 100000UNIT/GM · ATC D01AA01 NYSTATIN · form Cream · route Topical · ingredients NYSTATIN 100000 UNIT/G · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Non-prescription drugs
Mycostatin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00029092: Mycostatin
Raw flags: notABenefit=Y, sec3=Y
Item: 840408004; group id 823; item number 2005; lccId None; manufacturer id BQU
Source form: Cr; strength: 100000U/g
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00029092
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=918
Therapeutic Notes (formulary)
Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.
Interchangeable products
Nyaderm · DIN 00716871 · $0.2037
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00029092
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 6, 2006 — choose a marketed DIN from the same-category list.
Mycostatin · DIN 00248169 · 100000U/mL · oral liquid
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-28 — choose a marketed DIN from the same-category list.Discontinued July 28, 2003 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-07-28 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mycostatin · DIN 00248169
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Daily cost (source): $0.2072
Health Canada: Cancelled post market since 2003-07-28 · brand MYCOSTATIN ORAL SUSPENSION 100000IU · ATC A07AA02 NYSTATIN · form Liquid · route Oral · ingredients NYSTATIN 100000 UNIT/ML · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Prescription
Mycostatin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00248169: Mycostatin
Raw flags: notABenefit=Y, sec3=Y
Item: 081204006; group id 14; item number 0018; lccId None; manufacturer id BQU
Source form: O/L; strength: 100000U/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00248169
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1474Interchangeable products
Jamp-Nystatin Oral Suspension USP · DIN 02433443 · $0.0518
Ratio-Nystatin · DIN 02194201 · $0.0518
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00248169
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 28, 2003 — choose a marketed DIN from the same-category list.
Mycostatin · DIN 00029556 · 100000U/g · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2002 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mycostatin · DIN 00029556
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Health Canada: Cancelled post market since 2002-07-30 · brand MYCOSTATIN ONT 100000IU/GM · ATC D01AA01 NYSTATIN · form Ointment · route Topical · ingredients NYSTATIN 100000 UNIT/G · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Non-prescription drugs
Mycostatin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00029556: Mycostatin
Raw flags: notABenefit=Y, sec3=Y
Item: 840408005; group id 823; item number 2006; lccId None; manufacturer id BQU
Source form: Oint; strength: 100000U/g
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00029556
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=832
Therapeutic Notes (formulary)
Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.Interchangeable products
Ratio-Nystatin · DIN 02194228 · $0.1277
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00029556
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2002 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D01A, G01A): coverage varies; not interchangeable
Clotrimazole (Clotrimaderm): general benefit, not a benefit
Ketoconazole (Nizoral): general benefit, not a benefit
Metronidazole (Noritate): general benefit, not a benefit
Miconazole nitrate (Micatin): general benefit
Terbinafine (Lamisil): general benefit
Terconazole (Terazol 7): general benefit, not a benefit
DIN 01926829: Flagystatin
Raw flags: sec3=Y
Item: 840416020; group id 831; item number 2024; lccId None; manufacturer id SAV
Source form: Vag Sup; strength: 500mg & 100000U
Recorded listing: General benefit
Source prices (unrounded): $3.8510; ministry $3.8510
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926829
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12654
Shortage status: resolved shortage (ended November 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926829
General benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-24 — choose a marketed DIN from the same-category list.Discontinued August 24, 2017 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2017-08-24 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Flagystatin · DIN 01926845
Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01
Health Canada: Cancelled post market since 2017-08-24 · brand FLAGYSTATIN · ATC G01AA51 NYSTATIN, COMBINATIONS, G01AA51 NYSTATIN, COMBINATIONS · form Cream · route Vaginal · ingredients NYSTATIN 100000 UNIT/4.5G, METRONIDAZOLE 500 MG/4.5G · company Sanofi-aventis canada inc · schedule Prescription
DIN 01926845: Flagystatin
Raw flags: sec3=Y
Item: 840416018; group id 831; item number 2023; lccId None; manufacturer id SAV
Source form: Vag Cr-App; strength: 500mg & 100000U/g
Recorded listing: General benefit
Source prices (unrounded): $0.6076; ministry $0.6076
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926845
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12996
Shortage status: resolved shortage (ended August 16, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926845
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 24, 2017 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D01A, G01A): coverage varies; not interchangeable
Clotrimazole (Clotrimaderm): general benefit, not a benefit
Ketoconazole (Nizoral): general benefit, not a benefit
Metronidazole (Noritate): general benefit, not a benefit
Miconazole nitrate (Micatin): general benefit
Terbinafine (Lamisil): general benefit
Terconazole (Terazol 7): general benefit, not a benefit
2 more in the class list below
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered
Matched class: 08:12:04 Antifungals
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMPHOTERICIN B
Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, TERBINAFINE HCL
08:12:04 Antifungals
· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (12) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered
Matched class: 84:04:08 Fungicides
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL
Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, TERCONAZOLE
84:04:08 Fungicides
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered
Matched class: 84:04:16 Other Anti-Infectives
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: SILVER SULFADIAZINE
Some products covered without a code (check the product listing): METRONIDAZOLE
84:04:16 Other Anti-Infectives
· 2 products · Listed, not a benefit · strengths: 10% · Top Sol
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:16
1. INDICATIONS
FLAGYSTATIN (metronidazole and nystatin) is indicated for:
• Mixed vaginal infection due to Trichomonas vaginalis and Candida albicans.
FLAGYSTATIN has antibacterial and antifungal properties. To reduce the development of drug-resistant
bacteria/fungi and maintain the effectiveness of FLAGYSTATIN and other antibacterial/antifungal drugs,
FLAGYSTATIN should be used only to treat proven or strongly suspected mixed vaginal infections.
1.1. Pediatrics
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not
authorized an indication for pediatric use.
1.2. Geriatrics
Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an
indication for geriatric use.
https://pdf.hres.ca/dpd_pm/00085865.PDF
PM date: 2026-08-21
Source product: FLAGYSTATIN; DIN 01926829; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Nyaderm · DIN 00716901
Shortage status: discontinued (2024-10-04, reported by TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716901
Nyaderm · DIN 00716871
Shortage status: active shortage (reported 2026-08-01, estimated to end 2027-03-26, last updated 2026-08-17); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716871
Ratio-Nystatin · DIN 02194201
Shortage status: active shortage (reported 2026-06-03, last updated 2026-06-04); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194201
Ratio-Nystatin · DIN 02194163
Shortage status: discontinued (2020-02-19, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02194163
For Mycostatin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.